O Kilkku
Overview
Explore the profile of O Kilkku including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sivenius J, Sarasoja T, Aaltonen H, Heinonen E, Kilkku O, Reinikainen K
Neurorehabil Neural Repair
. 2002 Apr;
15(3):183-90.
PMID: 11944739
Objective: Selegiline (L-deprenyl) is a selective monoamine oxidase B (MAO-B) inhibitor used in the treatment of Parkinson's disease. In addition, it is thought to rescue neurons with a loss of...
2.
Kanerva H, Kilkku O, Heinonen E, Helminen A, Rouru J, TARPILA S, et al.
Biopharm Drug Dispos
. 2000 Apr;
20(7):327-34.
PMID: 10760840
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2...
3.
Kanerva H, Kilkku O, Helminen A, Rouru J, Scheinin M, Huupponen R, et al.
Int J Clin Pharmacol Ther
. 1999 Dec;
37(12):589-97.
PMID: 10599951
Unlabelled: Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties. The aim of this study...
4.
Kanerva H, Vilkman H, Nagren K, Kilkku O, Kuoppamaki M, Syvalahti E, et al.
Psychopharmacology (Berl)
. 1999 Aug;
145(1):76-81.
PMID: 10445375
Rationale: Deramciclane fumarate is a new 5-HT2A and 5-HT2C receptor antagonist with putative anxiolytic effects. In the present study the binding of deramciclane to serotonin 5-HT2A receptors in frontal cortex...
5.
Aaltonen H, Kilkku O, Heinonen E, Maki-Ikola O
BMJ
. 1998 Dec;
317(7172):1586-7.
PMID: 9890764
No abstract available.
6.
Olanow C, Myllyla V, Sotaniemi K, Larsen J, Palhagen S, Przuntek H, et al.
Neurology
. 1998 Sep;
51(3):825-30.
PMID: 9748034
Introduction: The Parkinson's Disease Research Group of the United Kingdom (PDRG-UK) reported increased mortality in PD patients treated with levodopa plus selegiline compared with those treated with levodopa alone. Methods:...
7.
Pirttila T, Koivisto K, Mehta P, Reinikainen K, Kim K, Kilkku O, et al.
Neurosci Lett
. 1998 Jul;
249(1):21-4.
PMID: 9672379
Levels of soluble amyloid beta protein (sAbeta), amyloid beta precursor protein (APP) and apolipoprotein E (apoE) were examined in cerebrospinal fluid (CSF) obtained twice, at baseline and after 3-year follow-up,...
8.
Maki-Ikola O, Kilkku O, Heinonen E
BMJ
. 1996 Mar;
312(7032):702; author reply 704-5.
PMID: 8597744
No abstract available.
9.
Alho O, Koivu M, Sorri M, Oja H, Kilkku O
Arch Otolaryngol Head Neck Surg
. 1994 Aug;
120(8):807-11.
PMID: 8049040
Objective: To examine at the population level which children were operated on for recurrent acute otitis media episodes, how ill they were, and what factors affected the operation rate. Design:...
10.
Alho O, Kilkku O, Oja H, Koivu M, Sorri M
Arch Otolaryngol Head Neck Surg
. 1993 Apr;
119(4):444-9.
PMID: 8457307
A random sample of 2512 children was monitored to age 2 years to study the biologic effects of various risk variables on acute otitis media using a new dynamic modeling...